Over the last decade we have successfully evaluated the use of a human skin explant assay for predicting acute GVHD in HLA-matched sibling transplants. In the present study, we modified GVHD prophylaxis on an individual patient basis depending on the GVHD outcome predicted by the skin explant model. We have summarised our previous data describing how the skin explant assay results correctly predict GVHD occurrence and severity in 45/56 patients (80%); P Ͻ 0.0001, 2 19.97, df = 1. In a further cohort of 19 patients, all were predicted to develop grade II or above GVHD. These patients were given increased GVHD prophylaxis with the addition of methotrexate and a significant reduction in the expected incidence of GVHD was observed (P = 0.02; 2 7.7, df = 1; Fisher exact test P = 0.04). The results from these studies suggest that modifying GVHD prophylaxis, based on skin explant assay results, may reduce the expected incidence and severity of GVHD. We suggest that the technique might be used for selective GVHD prophylaxis in T cell non-depleted HLA matched sibling transplants.
cal outcome. 6 More recently, Hromadníková et al 8, 9 have used the assay to predict correctly acute GVHD outcome in a cohort of paediatric patients with a predictive value of 91%. 8 In the present study, we have summarised skin explant assay data from 56 HLA-and DR-matched transplants, details of which have been previously described. 6, 7 In a further 19 HLA-matched bone marrow transplant patients, all patients were predicted to develop GVHD grade II or above and in these patients GVHD prophylaxis was modified by addition of methotrexate to routine cyclosporin prophylaxis. A reduction in the expected incidence of GVHD, above grade II, was significant (P = 0.04, Fisher exact test).
Materials and methods

Ethical and informed consent
Local ethics committee approval (Newcastle and Prague) and informed consent were obtained for all patients and donors in this study.
Patients
Results from 56 adult patients and their HLA-matched, mixed lymphocyte culture-negative, sibling donor pairs have been reported previously. 6, 7 Skin explant assay results from these patients were correlated with GVHD occurrence post-transplant and analysed by Chi-square (Table 1 ). All patients in this cohort were treated with cyclosporin alone (5 mg/kg) as standard GVHD prophylaxis. A further 19 patients (16 adults and three children), all predicted to develop acute GVHD grade II or above, were given increased GVHD prophylaxis. During this time period 11 patients (10 adults and one child) not predicted to develop GVHD grade II or above were given cyclosporin alone prophylaxis. All patients received T cell non-depleted grafts from HLA-identical sibling donors. The underlying diseases in the transplanted patients were chronic myeloid leukaemia (CML, n = 7), acute myeloid leukaemia (AML, n = 16), acute lymphoblastic leukaemia (ALL, n = 4), nonHodgkin's lymphoma (NHL, n = 1), Hodgkin's disease (HD, n = 1) and mylodysplastic syndrome (MDS, n = 1). Chi-square analysis data, P = 0.0001, df 1, 2 19 .976.
Conditioning regimens for the transplants
The adult patients were conditioned with fractionated total body irradiation (TBI) (six fractions at 200 cGy, given at a dose of 25 cGy/min) and melphalan, 3 mg/kg except in one case where cyclophosphamide (120 mg/kg) was given. The paediatric patients (age range, 5-12 years) were conditioned depending on diagnosis and stage of disease. Some children were conditioned with 12 Gy TBI (six fractions 200 cGy) with etoposide (VP-16, 60 mg/kg), together with local irradiation to the testes and central nervous system when indicated. Alternative conditioning consisted of busulphan (16 mg/kg, total dose) and cyclophosphamide (120 mg/kg, total dose) with or without melphalan (140 mg/m 2 ).
GVHD prophylaxis
All patients predicted to develop grade II or above GVHD were given increased GVHD prophylaxis, in the form of cyclosporin (3-5 mg/kg) and methotrexate (10-15 mg/m 2 ) i.v. either on days 1, 3, 6 and 11 (paediatric patients) or on days 1, 3, 6 or 4 and 10 (adult patients). Patients predicted to develop grade I or less GVHD were given cyclosporin (3-5 mg/kg) alone prophylaxis.
HLA-typing
All patients and donors in this study were originally tested by conventional serology for HLA-A and -B alleles 10 along with low resolution molecular typing of DRB1 using PCR SSP. 11 When DNA was available, retrospective testing was also performed on patient/donor pairs to high level (allele) resolution for DRB1*, DQB1*, Cw and DPB1* using PCR SSP and PCR SSO, respectively. 12 
Preparation of peripheral blood mononuclear cells (PBMCs)
Peripheral blood was collected from patients and their marrow donors before transplantation. PBMCs were separated from heparinized venous blood over lymphoprep (Nycomed Pharma, Oslo, Norway) by density gradient centrifugation. Cells were then washed twice with Earle's balanced salt solution (EBSS, Gibco, UK) and resuspended in RPMI 1640 medium (Gibco) supplemented with 10% heat-inactivated human AB serum, l-glutamine and antibiotics (RPMI-AB).
Skin explant assay
The skin explant assay has recently been described in detail.
4,6-8 Briefly, donor responder lymphocytes from patient and donor mixed lymphocyte cultures were cocultured for 3 days with patient skin biopsies. After 3 days of incubation the explants were fixed in 10% buffered formalin, sectioned and stained with haematoxylin and eosin. The histopathological evaluation of skin explants was performed blind and independently by one of two histopathologists (LS/MC). The grading system of graft-versus-host reaction (GVHR) was based on that described by Lerner et al. 13 . 4, [6] [7] [8] In order to check for autoreactivity, additional controls consisted of responder cells from an autologous MLR control (irradiated patient lymphocytes × patient lymphocytes). Only tests where controls gave negative (grade 0 or I GVHR) results on patient biopsies were used in this study. 
Statistical analysis
The difference between skin explant assay results and GVHD status was determined by Chi-squared analysis and the Fisher exact test.
Results
Use of the skin explant assay for predicting graft-versushost disease
We have summarised and analysed data from 56 patient and donor pairs, previously reported separately, from our laboratory ( Table 1) . GVHD occurrence of grade II or above was predicted for 23 patients; none of these patients received increased GVHD prophylaxis. Eighteen of 23 patients with positive skin biopsies developed GVHD posttransplant. Conversely, skin explant results predicted mild GVHD (grade I) in 33 assays; 27 of these cases developed grade I GVHD. Overall the skin explant assay correlated with GVHD outcome in 45/56 (80%) cases with six false negative and five false positive results (P Ͻ 0.0001; 2 19.97; df = 1).
Use of the skin explant assay results for modifying GVHD prophylaxis
Nineteen patients, predicted to develop GVHD grade II or above, were given increased GVHD prophylaxis. Eight patients developed grade II or above GVHD (see Table 2 ).
From reported results of the skin explant assay, in both adult and paediatric cases, 8, 9, 14 positive skin explant results predict GVHD in 80-90% 6, 8, 14 of patients. Using these results, we would predict that 15 (80%) or more patients would develop GVHD. However only eight of 19 developed the disease, following modification of prophylaxis, and this difference from the expected incidence Table 2 Skin explant assay predicting GVHD occurrence and effect of increased GVHD prophylaxis on clinical outcome Of the 13 transplant patients who were predicted to develop grade III GVHD only three developed severe (grade III-IV) GVHD.
During this time period, 11 patients were predicted to develop grade I or less GVHD. Results for seven of these patients are also included in Table 1 and shown individually in Table 3 . Of these 11 patients, six developed grade 0 or I GVHD; three patients developed mild grade II disease, one patient grade III and one patient grade IV GVHD. All had been given cyclosporin alone as GVHD prophylaxis. In this small cohort of patients, the skin explant model was not as predictive of outcome as expected. Only six of 11 patients tested had grade 0-I GVHD (Table 3) .
Discussion
We have used a skin explant model, originally described by Vogelsang et al 14 in a number of previous studies for predicting GVHD in HLA-identical patient/donor pairs. 4, 6, 7 The original work of Vogelsang, which included paediatric cases, described an expected incidence of GVHD of 85% if the skin explant assay was positive. We confirmed this data [6] [7] [8] and have summarised the results in this present report.
The overall objective of this present study was to reduce the incidence and severity of GVHD by modifying GVHD prophylaxis on an individual patient basis. We aimed to achieve this by prior knowledge of the skin explant assay results. In a small selected cohort of 11 patients who were predicted not to develop GVHD, were given cyclosporinalone prophylaxis. A higher incidence than expected developed GVHD; six of 11 of these patients developed grade II or above GVHD. Three patients had mild disease (grade II) and eight of 11 are alive and well with no inci-861 Table 3 Clinical outcome and GVHD grade in patients with negative skin explant results and given cyclosporin-alone prophylaxis dence of relapse of disease. All false negative results were observed in either AML or CML patients. This result has been observed in previous reports 4, 14 and may be due to the underlying nature of the disease.
Nineteen patients were predicted to develop grade II or above GVHD and our results suggest that cyclosporin and methotrexate reduced the expected incidence of patients developing GVHD from 15/19 (80%) to eight of 19, a reduction in the expected incidence of 42%.
Of 13 transplant patients predicted to develop grade III GVHD, only three of 13 developed severe grade III-IV GVHD. This result compares favourably with previous results when three of five patients, on cyclosporin-alone prophylaxis, developed a predicted grade III GVHD. 6, 7 Interestingly, in this small cohort, all but one patient who had a positive skin explant result and developed grade II or above GVHD, also developed gut and or liver disease (results not shown). We aim therefore to compare the skin explant model results with organ involvement and the Glucksberg 15 grading (manuscript in preparation). Several randomised prospective trials have demonstrated that cyclosporin plus methotexate was superior to either drug alone in preventing GVHD. [16] [17] [18] However Storb et al 18 demonstrated that whilst there was no difference in relapse rates in CML between cyclosporin plus/minus methotrexate, in acute non-lymphoblastic leukaemia relapse-free survival was better in the cyclosporin-alone group (16% vs 29%), although this did not reach significance (P = 0.29).
Frassoni et al 19 and the Working Party of the European Group for Blood and Marrow Transplantation (EBMT) reported that in AML and ALL a reduction in transplantrelated mortality was associated with cyclosporin plus methotrexate GVHD prophylaxis. This reduction in transplant-related mortality was without loss of an antileukaemic effect. However, reducing GVHD prophylaxis may allow an improved graft-versus-leukaemia effect whilst not compromising those patients not predicted to develop GVHD. Storb et al 20 have modified the duration of cyclosporin prophylaxis in non-GVHD or resolved GVHD patients post-transplant in order to reduce the incidence of chronic GVHD. The results suggested that cyclosporin could safely be discontinued early in patients who never had evidence of acute GVHD, but those patients with preceding acute GVHD may have benefited from a longer course of the drug in order to delay the onset and possibly the incidence of chronic GVHD. More recently Elmaagacli et al 21 have similarly demonstrated that cyclosporin A withdrawal in relapsing CGL and AML patients could initiate a graft-versus-leukaemia (GVL) reaction, often however, also giving rise to severe GVHD.
The use of single or combined therapy for either achieving GVL responses or increasing the risk of leukaemic relapse remains controversial. Aschan et al 22 have shown an increased risk of relapse when methotrexate was combined with cyclosporin compared to monotherapy. However, Ringdén et al 23 in an IBMTR study gave no evidence that combined therapy gave rise to more relapses than cyclosporin alone. Due to the variables involved in interpreting transplant data such as donor-recipient sex-matching, type of leukaemia, and effects of differing GVHD prophylaxis on remission states it is not surprising that results are often controversial.
In our present study we aimed to observe the affect of modifying therapy when patients were predicted at high risk of developing GVHD.
In our centre (Newcastle Regional BMT Centre) we used cyclosporin alone to prevent acute GVHD in a cohort of HLA-matched sibling transplants and demonstrated a low incidence of acute GVHD (33.7%) in 107 patients studied. 24 Of the patients surviving greater than 100 days, 44 (58%), did not develop chronic GVHD. Those patients who developed acute GVHD did not necessarily develop chronic GVHD and visa versa. This confirms our earlier observations 4 which demonstrated that the skin explant model did not correlate with chronic GVHD.
Using results from the skin explant assay, those patients predicted to develop GVHD are now given increased GVHD prophylaxis in the form of methotrexate and, as shown by this study, the predicted incidence of GVHD was significantly reduced in our cohort of patients.
In conclusion, this is the first report of using the skin explant assay results for individualising patient GVHD prophylaxis. Results from two independent centres (Newcastle and Prague) demonstrate the value of the skin explant assay for predicting GVHD occurrence in HLAgenotypical identical sibling transplants given cyclosporin-alone GVHD prophylaxis. Altering prophylaxis in the form of cyclosporin plus methotrexate appears to reduce GVHD in those BMT patients predicted to develop the disease.
We should emphasise that many transplant centres use cyclosporin plus methotrexate as standard GVHD prophylaxis. In this setting, from our present results, the skin explant model would clearly not be as 'predictive'. Further studies involving the use of different preparative regimens, less matched donor and recipients and patients within different age groups are currently being carried out to determine the possible wider use of the skin explant model. Collaboration between teams of stem cell transplant clinicians will also enable the evaluation of GVHD (and GVHR in skin explant biopsies) to be standardised and less subjective and variable between centres. This aspect would further improve the interpretation of transplant data.
Further improvements in GVHD prophylaxis based on predicted outcome should improve survival and reduce morbidity due to GVHD in future cohorts of allograft patients including PBSC recipients. In this regard, to date, five patient-donor pairs of HLA-matched T cell nondepleted PBSC transplants have been tested using the skin explant model. All received GVHD prophylaxis in the form of cyclosporin and methotrexate. The skin explant model continued to predict GVHD in three of five of these patients. These results may reflect the increase in the number of T cells present in a PBSC transplant compared with bone marrow and further studies are in progress on the use of the skin explant in related and matched unrelated donor transplants involving PBSC harvests.
Current research in our laboratory is involved in the development of a risk index for GVHD in HLA-matched sibling transplants, including the use of the skin explant assay, minor histocompatibility typing 25 and patient and donor cytokine gene polymorphisms, 26 with the aim of improving future clinical GVHD prophylaxis regimens. The skin explant assay is also being tested in different cohorts of patients in collaborating BMT centres within Europe to demonstrate its effectiveness for predicting GVHD and when necessary modifying GVHD prophylaxis in cohorts of adult and paediatric patients. 27 
